Martin Akerman, CTO, Envisagenics Spyro Mousses, CEO, Systems Oncology
11:00 - 11:30am
How to Approach Predictive ADMET Modeling and Maximize its Impact on Drug Discovery Projects • Retrospective analysis of results in ADMET
• The importance of culture – getting the chemistry teams in the right mindset, using the advanced AI/ML technologies, and willing to incorporate the predictions and move ahead using models – use cases
• ADMET models and technologies are better so what’s the future for solving the potency and selectivity challenges?
Barun Bhhatarai, Investigator, Novartis Institutes for BioMedical Research (NIBR) Marcel Hop, Vice President, Drug Metabolism and Pharmacokinetics, Genentech
11:30 - 11:45
Innovation Spotlight Presentations
Rafael Rosengarten, PhD, CEO, Genialis • Tackling the "Small Data Problem": Integration and Harmonization Strategies To Unlock the Potential of Clinical Trial Datasets
Ariel Katz, Co-Founder, H1 • Leveraging AI to Aggregate Healthcare Data and HCP Data
11:45 - 12:30
Leader Perspectives in Clinical Development: Achieving Consistency in Validating & Operationalizing the AI/ML Automation Efforts Transforming Biopharma
Although certain intelligent automation technologies have been used in some PV areas for years (e.g. rule-based software, auto-coding, auto-narrative generation, etc.), rapid development of newer technologies (e.g. machine learning, natural language processing) has outpaced some PV regulations. Therefore, continued innovation will be more likely and ultimately more successful if companies and 3rd party developers can be reasonably assured they have adequately validated their systems and automated processes.
A panel of biopharma leaders will delve into:
• IAO in the past and now – how it’s transforming our work
• Specific Intelligent Automation Opportunities in Pharmacovigilance Solutions
- Short Term - Validation Proposal
- Long Term - to Transform and Accelerate
Moderator Neal Grabowski, MEng, MBA, Director, Safety Data Science, AbbVie; Intelligent Automation Opportunities (IAO) in PV Workstream Lead, TransCelerate BioPharma, Inc.
Danielle Abatemarco, MSc, Scientific Publications Lead, WorldWide Patient Safety, Bristol-Myers Squibb; Intelligent Automation Opportunities (IAO) Workstream Member, TransCelerate BioPharma, Inc. Andrew Bate, PhD, Head of Safety Innovation & Analytics, GSK Pharmacovigilance Steering Committee Member, TransCelerate BioPharma, Inc.
12:30 - 1:00pm
Unconventional AI/ML for the Biomedical Sciences
• Understanding driver biology and Identifying causal drug targets that are driving disease ideology
• Going after the means and the capabilities to drive more effective therapeutics with far fewer associated side effects
• Quantum computing approaches to analysis of multi-omic data
Thomas W. Chittenden, PhD, DPhil, PStat, Chief Data Science Officer, Genuity Science
Monday, October 26, 2020 at 10:30 AM
Eastern Time (US & Canada)
Duration:2 hours 30 minutes
Who can attend?Anyone with the event link can attend
Passionate about business transformations that accelerate growth, efficiency gains, cost reductions, and competitive advantage for market leaders as well as up-and-coming innovators with next-generation ideas.
Dr. Martin Akerman is the Co-founder and CTO of Envisagenics. He is the inventor of the SpliceCore software platform, born out of his extensive research experience at the intersection of biology and data science and his vision of discovering RNA...
Dr. Mousses is the cofounder and CEO of Systems Oncology LLC. He is widely recognized as a leading scientist in the application of genomics, systems biology, and machine learning to improve and accelerate cancer drug discovery and development. ...
Rafael leads Genialis’ effort to integrate and mine vast and diverse sources of biomedical knowledge to realize the promise of precision medicine and therapeutic discovery. He spent nearly 20 years in biomedical research prior to Genialis,...
Ariel started his first company in college, ResearchConnection, to help connect students with research opportunities. That company grew to over 40 universities and was eventually acquired by the Bill and Melinda Gates Foundation and the Ewing...
Dr. Thomas Chittenden is Chief Data Science Officer and Founding Director of the Genuity Science Advanced Artificial Intelligence Research Laboratory. Dr. Chittenden is responsible for development and execution of our global AI/ML R&D strategy....
H1 is a data platform for the global healthcare community to track, analyze, and glean insights into the people, organizations, and findings happening every day. With the world’s largest database of over 8million HCPs and Social Media coverage,...
Genialis is a computational precision medicine company focused on new ways to treat disease. Blending bioinformatics and machine learning, Genialis models data across translational research and clinical development. Genialis is trusted by...
Genuity Science is a contract genomics and data-sourcing, -analytics and -insights organization headquartered in Boston, MA, USA with offices in Ireland and Iceland. Genuity partners with global biopharma companies to offer deep end-to-end...
We connect the industry’s science minds, AI technology experts, technologists, and strategy leaders through in-person and virtual events and digital content.
Our large community of industry leaders are passionate about the work they do and are dedicated to working at the intersection of science and technology. We collaborate with our industry experts to convene engaged discussions and facilitate the translation of AI/ML technologies into patient impact.